Incidence Rate of Relapse After Treatment of Disseminated Tuberculosis
The incidence rate of recurrent tuberculosis after successful treatment is approximately 2.26 per 100 person-years, with relapse (rather than reinfection) accounting for approximately 70% of recurrences overall, though this varies significantly by TB incidence setting 1.
Key Epidemiological Data
The most comprehensive systematic review and meta-analysis examining recurrent TB found 1:
- Overall recurrence rate: 2.26 per 100 person-years (95% CI 1.87-2.73)
- Relapse proportion: 70% of all recurrences (95% CI 63-77%)
- Reinfection proportion: 30% of recurrences
Critical Modifying Factors
The incidence varies substantially based on epidemiological context:
Low TB incidence settings:
- Recurrence rate: 1.47 per 100 person-years (95% CI 0.87-2.46)
- Relapse accounts for 83% of recurrences (95% CI 75-89%)
High TB incidence settings:
- Recurrence rate: 4.10 per 100 person-years (95% CI 2.67-6.28)
- Relapse accounts for only 59% of recurrences (95% CI 42-74%)
- Reinfection becomes increasingly important
Timing and Risk Factors
Most relapses occur within 6-12 months after completion of therapy 2.
High-Risk Patients for Relapse
Patients at elevated risk include those with 2:
- Extensive disease at baseline (including miliary/disseminated TB)
- Positive sputum cultures after completion of intensive phase (2 months)
- Inadequate treatment adherence (non-DOT regimens)
- HIV co-infection
- Highly intermittent treatment regimens
- Non-rifamycin-containing regimens
Important Caveat on Sensitivity
While culture-positive status at 2 months is associated with relapse risk, its sensitivity for predicting relapse is low 2, meaning many patients who relapse will have had negative cultures at 2 months.
Drug Susceptibility in Relapse
In patients treated with directly observed therapy (DOT) using rifamycin-containing regimens, the majority of relapses occur with drug-susceptible organisms 2. However, acquired drug resistance risk is substantial in patients who:
- Received self-administered therapy (SAT)
- Had irregular treatment
- Were treated with highly intermittent regimens in HIV setting
- Received non-rifamycin continuation phase
- Had unrecognized baseline resistance
Mortality Context for Disseminated TB
While the question asks about relapse rates, it's critical to note that disseminated/miliary TB carries mortality rates exceeding 30% even with treatment 3, and 86% mortality in disseminated TB without miliary pattern on chest radiograph 4. This underscores that preventing initial treatment failure is paramount, as relapse adds additional mortality risk.
Clinical Implications
For disseminated TB specifically:
- Standard 6-month HRZE-HR regimens apply to isolated pulmonary miliary TB
- Extended 9-12 month therapy is required for CNS complications 3
- Drug-resistant cases demand 18-24 month individualized regimens 3
The substantial recurrence risk (2.26 per 100 person-years) means approximately 11-13% of successfully treated patients will experience recurrence within 5 years, with the majority being true relapses rather than reinfections in low-incidence settings.